A novel microfluidic liposomal formulation for the delivery of the SN-38 camptothecin: characterization and in vitro assessment of its cytotoxic effect on two tumor cell lines

References

• ChenAYLiuLFDNA topoisomerases: essential enzymes and lethal targetsAnnu Rev Pharmacol Toxicol1994341912188042851
   PubMed Web of Science ®Google Scholar
• LiTKLiuLFTumor cell death induced by topoisomerase-targeting drugsAnnu Rev Pharmacol Toxicol200141537711264450
   PubMed Web of Science ®Google Scholar
• TeicherBANext generation topoisomerase I inhibitors: rationale and biomarker strategiesBiochem Pharmacol20087561262127118061144
   PubMed Web of Science ®Google Scholar
• PommierYTopoisomerase I inhibitors: camptothecins and beyondNat Rev Cancer200661078980216990856
   PubMed Web of Science ®Google Scholar
• LacombeOKZumaAAda SilvaCCde SouzaWMottaMCEffects of camptothecin derivatives and topoisomerase dual inhibitors on Trypanosoma cruzi growth and ultrastructureJ Negat Results Biomed20141311124917086
   PubMedGoogle Scholar
• Randall-WhitisLMMonkBJTopotecan in the management of cervical cancerExpert Opin Pharmacother20078222723617257092
   PubMed Web of Science ®Google Scholar
• LiewSTYangLXDesign, synthesis and development of novel camptothecin drugsCurr Pharm Des200814111078109718473856
   PubMed Web of Science ®Google Scholar
• SlatterJGSuPSamsJPSchaafLJWienkersLCBioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactionsDrug Metab Dispos19972510115711649321519
   PubMed Web of Science ®Google Scholar
• WuMHYanBHumerickhouseRDolanMEIrinotecan activation by human carboxylesterases in colorectal adenocarcinoma cellsClin Cancer Res2002882696270012171903
   PubMed Web of Science ®Google Scholar
• Garcia-CarboneroRSupkoJGCurrent perspectives on the clinical, experience pharmacology, and continued development of the camptothecinsClin Cancer Res20028364166111895891
   PubMed Web of Science ®Google Scholar
• DawidczykCMKimCParkJHState-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicinesJ Control Release201418713314424874289
   PubMed Web of Science ®Google Scholar
• EstanqueiroMAmaralMHConceiçãoJSousa LoboJMNanotechnological carriers for cancer chemotherapy: the state of the artColloids Surf B Biointerfaces201512663164825591851
   PubMed Web of Science ®Google Scholar
• Pérez-HerreroEFernández-MedardeAAdvanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapyEur J Pharm Biopharm201593527925813885
   PubMed Web of Science ®Google Scholar
• ZylberbergCMatosevicSPharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscapeDrug Deliv20162393319332927145899
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRLiposomal drug delivery systems: from concept to clinical applicationsAdv Drug Deliv Rev2013651364823036225
   PubMed Web of Science ®Google Scholar
• PercheFTorchilinVPRecent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingJ Drug Deliv2013201370526523533772
   PubMedGoogle Scholar
• SenKMandalMSecond generation liposomal cancer therapeutics: transition from laboratory to clinicInt J Pharm20134481284323500602
   PubMedGoogle Scholar
• KraftJCFreelingJPWangZHoRJEmerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systemsJ Pharm Sci20141031295224338748
   PubMed Web of Science ®Google Scholar
• TorchilinVPMultifunctional, stimuli-sensitive nanoparticulate systems for drug deliveryNat Rev Drug Discov2014131181382725287120
   PubMed Web of Science ®Google Scholar
• BozzutoGMolinariALiposomes as nanomedical devicesInt J Nanomedicine20151097599925678787
   PubMed Web of Science ®Google Scholar
• ChoiJYRamasamyTTranTHSystemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growthJ Mater Chem B20153408416
   PubMed Web of Science ®Google Scholar
• MadniASarfrazMRehmanMLiposomal drug delivery: a versatile platform for challenging clinical applicationsJ Pharm Pharm Sci201417340142625224351
   PubMed Web of Science ®Google Scholar
• WickiAWitzigmannDBalasubramanianVHuwylerJNanomedicine in cancer therapy: challenges, opportunities, and clinical applicationsJ Control Release201520013815725545217
   PubMed Web of Science ®Google Scholar
• PanahiYFarshbafMMohammadhosseiniMRecent advances on liposomal nanoparticles: synthesis, characterization and biomedical applicationsArtif Cells Nanomed Biotechnol201745478879928278586
   PubMed Web of Science ®Google Scholar
• CasadóAGiuffridaMCSagristáMLLangmuir monolayers and differential scanning calorimetry for the study of the interactions between camptothecin drugs and biomembrane modelsBiochim Biophys Acta20161858242243326656185
   PubMed Web of Science ®Google Scholar
• FarokhzadOCLangerRImpact of nanotechnology on drug deliveryACS Nano200931162019206243
   PubMed Web of Science ®Google Scholar
• RamasamyTHaidarZSTranTHLayer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugsActa Biomater201410125116512725169256
   PubMed Web of Science ®Google Scholar
• RamasamyTRuttalaHBGuptaBSmart chemistry-based nanosized drug delivery systems for systemic applications: a comprehensive reviewJ Control Release201725822625328472638
   PubMed Web of Science ®Google Scholar
• EmersonDLLiposomal delivery of camptothecinsPharm Sci Technolo Today20003620520910840391
   PubMedGoogle Scholar
• HatefiAAmsdenBCamptothecin delivery methodsPharm Res200219101389139912425455
   PubMed Web of Science ®Google Scholar
• ChusteckaZLiposomal Irinotecan (MM-398) Approved in Pancreatic Cancer. Medscape News. FDA approvals: [2p.] Available from: https://www.medscape.com/viewarticle/853072Accessed October 22, 2015
   Google Scholar
• SadzukaYHirotsuSHirotaSEffective irinotecan (CPT-11)- containing liposomes: intraliposomal conversion to the active metabolite SN-38Jpn J Cancer Res199990222623210189894
   PubMedGoogle Scholar
• BalaVRaoSBoydBJPrestidgeCAProdrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38J Control Release20131721486123928356
   PubMed Web of Science ®Google Scholar
• SadzukaYTakabeHSonobeTLiposomalization of SN-38 as active metabolite of CPT-11J Control Release20051082–345345916182400
   PubMed Web of Science ®Google Scholar
• BanghamADStandishMMWatkinsJCDiffusion of univalent ions across the lamellae of swollen phospholipidsJ Mol Biol19651312382525859039
   PubMed Web of Science ®Google Scholar
• JahnAVreelandWNDeVoeDLLocascioLEGaitanMMicrofluidic directed formation of liposomes of controlled sizeLangmuir200723116289629317451256
   PubMed Web of Science ®Google Scholar
• YuBLeeRJLeeLJMicrofluidic methods for production of liposomesMethods Enzymol200946512914119913165
   PubMed Web of Science ®Google Scholar
• Guimarães Sá CorreiaMBriugliaMLNiosiFLamprouDAMicrofluidic manufacturing of phospholipid nanoparticles: stability, encapsulation efficacy, and drug releaseInt J Pharm20175161–2919927840162
   PubMedGoogle Scholar
• StewartJCColorimetric determination of phospholipids with ammonium ferrothiocyanateAnal Biochem1980104110146892980
   PubMed Web of Science ®Google Scholar
• ArturssonPPalmKLuthmanKCaco-2 monolayers in experimental and theoretical predictions of drug transportAdv Drug Deliv Rev2001461–3274311259831
   PubMed Web of Science ®Google Scholar
• FerreiraDAdegaFChavesRThe importance of cancer cell lines as in vitro models in cancer methylome analysis and anticancer drugs testingLópez-CamarilloCAréchaga-OcampoEOncogenomics and Cancer Proteomics-Novel Approaches in Biomarkers Discovery and Therapeutic Targets in CancerInTechOpen2013139166 Available from: https://cdn.intechopen.com/pdfs-wm/43632.pdf
   Google Scholar
• MosmannTRapid calorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assaysJ Immunol Methods1983651–255636606682
   PubMed Web of Science ®Google Scholar
• FriedJPerezAGClarksonBDFlow cytofluorometric analysis of cell cycle distributions using propidium iodide. Properties of the method and mathematical analysis of the dataJ Cell Biol197671117218161966
   PubMed Web of Science ®Google Scholar
• ChanFKMoriwakiKDe RosaMJDetection of necrosis by release of lactate dehydrogenase activityMethods Mol Biol2013979657023397389
   PubMedGoogle Scholar
• WolterbeekHTvan der MeerAJOptimization, application, and interpretation of lactate dehydrogenase measurements in microwell determination of cell number and toxicityAssay Drug Dev Technol20053667568216438662
   PubMed Web of Science ®Google Scholar
• KongGDewhirstMWHyperthermia and liposomesInt J Hyperthermia199915534537010519688
   PubMed Web of Science ®Google Scholar
• HattoriYShiLDingWNovel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumorsJ Control Release20091361303719331859
   PubMed Web of Science ®Google Scholar
• CasadóASagristáMLMoraMFormulation and in vitro characterization of thermosensitive liposomes for the delivery of irinotecanJ Pharm Sci2014103103127313825091422
   PubMed Web of Science ®Google Scholar
• GargSHeuckSIpSRamsayEMicrofluidics: a transformational tool for nanomedicine development and productionJ Drug Target201624982183527492254
   PubMed Web of Science ®Google Scholar
• CarugoDBottaroEOwenJStrideENastruzziCLiposome production by microfluidics: potential and limiting factorsSci Rep201662587627194474
   PubMed Web of Science ®Google Scholar
• ZhangJAXuanTParmarMDevelopment and characterization of a novel liposome-based formulation of SN-38Int J Pharm20042701–29310714726126
   PubMed Web of Science ®Google Scholar
• KligmanAMTopical pharmacology and toxicology of dimethyl sulfoxide. 1JAMA196519379680414329978
   PubMed Web of Science ®Google Scholar
• de MénorvalMAMirLMFernándezMLReigadaREffects of dimethyl sulfoxide in cholesterol-containing lipid membranes: a comparative study of experiments in silico and with cellsPLoS One201277e4173322848583
   PubMed Web of Science ®Google Scholar
• MalininTIPerryVPToxicity of dimethyl sulfoxide on HeLa cellsCryobiology19674290964171657
   PubMed Web of Science ®Google Scholar
• Da ViolanteGZerroukNRichardIProvotGChaumeilJCArnaudPEvaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell culturesBiol Pharm Bull200225121600160312499647
   PubMed Web of Science ®Google Scholar
• CasadóAMoraMSagristáMLImproved selectivity and cytotoxic effects of irinotecan via liposomal delivery: a comparative study on Hs68 and HeLa cellsEur J Pharm Sci2017109657728735042
   PubMed Web of Science ®Google Scholar
• García-DíazMNonellSVillanuevaADo folate-receptor targeted liposomal photosensitizers enhance photodynamic therapy selectivity?Biochim Biophys Acta2011180841063107121215723
   PubMed Web of Science ®Google Scholar
• RamasamyTRuttalaHBChitrapriyaNEngineering of cell microenvironment-responsive polypeptide nanovehicle co-encapsulating a synergistic combination of small molecules for effective chemotherapy in solid tumorsActa Biomater20174813114327794477
   PubMed Web of Science ®Google Scholar
• KakuYTsuchiyaAKannoTNishizakiTIrinotecan induces cell cycle arrest, but not apoptosis or necrosis, in Caco-2 and CW2 colorectal cancer cell linesPharmacology2015953–415415925833236
   PubMed Web of Science ®Google Scholar
• MorandiESeveriniCQuercioliDGene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell linesMol Cancer200876618694480
   PubMed Web of Science ®Google Scholar
• RivoryLPBowlesMRRobertJPondSMConversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesteraseBiochem Pharmacol1996527110311118831730
   PubMed Web of Science ®Google Scholar
• HaugKKravikKLDe AngelisPMCellular response to irinotecan in colon cancer cell lines showing differential response to 5-fluorouracilAnticancer Res2008282A58359218506996
   PubMed Web of Science ®Google Scholar
• KimHYoonSCLeeTYJeongDDiscriminative cytotoxicity assessment based on various cellular damagesToxicol Lett20091841131718992794
   PubMed Web of Science ®Google Scholar
• HeRDuYLingLNanoformulation of dual bexarotene-tailed phospholipid conjugate with high drug loadingEur J Pharm Sci201710019720428088372
   PubMed Web of Science ®Google Scholar